Aeolus Pharmaceuticals completes $1.5 million financing
Aeolus Pharmaceuticals, Inc. announced today that it completed a $1.5 million financing with two existing institutional shareholders, both of which are affiliates of Xmark Opportunity Partners, LLC. Under the terms of the financing agreement, Aeolus received $1.5 million in gross proceeds in exchange for 5,357,143 shares of Aeolus Pharmaceuticals common stock, and 5 year warrants to
Sanofi-Aventis said Friday it has completed its $20.1 billion buyout of specialty drugmaker Genzyme Corp.